A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the
cancer from getting worse in people with relapsed or refractory multiple myeloma. It will be
compared to another medicine called pomalidomide, given with dexamethasone with people with
the same condition. Relapsed means the previous cancer treatment stopped working, over time.
Refractory means they did not respond to previous cancer treatment. Another aim is to check
for side effects from the study medicines.
At the first visit, the study doctor will check who can take part. Participants who can take
part will be picked for 1 of 2 treatments by chance.
- Ixazomib capsules, given with dexamethasone tablets
- Pomalidomide capsules, given with dexamethasone tablets
All participants will take their study medicine on specific days during a 28-day cycle.
The 1st dose of study medicines in each 28-day cycle will take place in the clinic, The other
doses of the study medicines will be taken at home. This will happen for 6 cycles. After
this, all study medicines will be taken at home.
After treatment, participants will visit the clinic every 12 weeks for a check-up.
If participants cannot attend their clinic for an important reason (for example, due to the
COVID-19 pandemic), the clinic will make alternative arrangements using their local
procedures.